MCF Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

MCF Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$1K	–	767
2022 Q1	$1K	Buy	+200	New	+$730	﹤0.01%	681
2021 Q4	–	Sell	-500	Closed	-$4K	–	105
2021 Q3	$4K	Hold	500	–	–	﹤0.01%	530
2021 Q2	$6K	Buy	+500	New	+$9.88K	﹤0.01%	478

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

MCF Advisors's BDTX Position: Q2 2022 in Review

MCF Advisors sold out of Black Diamond Therapeutics (BDTX) in Q2 2022, closing a stake of 200 shares — an estimated $1K sold.

MCF Advisors first reported a position in BDTX in Q2 2021 and held it in 3 quarters. The position peaked at $6K in Q2 2021. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2022.

MCF Advisors reported no remaining Black Diamond Therapeutics position as of Q2 2022 after selling out during the quarter.
MCF Advisors sold 200 Black Diamond Therapeutics shares in Q2 2022, an estimated $1K.
MCF Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 3 quarters.
MCF Advisors's Black Diamond Therapeutics position peaked at $6K in Q2 2021.
74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2022.

Based on MCF Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.